Cadrenal Therapeutics (CVKD) Amended Form 144 Discloses Insider Sale

Rhea-AI Filing Summary

Cadrenal Therapeutics, Inc. (CVKD) filed an amended Form 144 disclosing a proposed sale of 3,836 common shares through Merrill Lynch on the NASQ exchange with an approximate aggregate market value of $53,455.56 and 2,046,854 shares outstanding. The shares were acquired on 01/25/2022 in a private placement from the company and were paid in full on that date. The filing reports no securities sold in the past three months for the account and includes the seller's representation that they are not aware of undisclosed material adverse information regarding the issuer.

Positive

• Transaction disclosed with key details including broker, share count, acquisition date, and aggregate market value
• Shares acquired in a private placement and paid in full on 01/25/2022, clearly stated
• Filer attests they are not aware of undisclosed material adverse information

Negative

• Filer identifiers (CIK/CCC) and certain contact fields are not provided in the supplied content, limiting traceability

Insights

Securities/Equity Analyst

TL;DR Small insider sale disclosed: 3,836 shares, ~$53.5k, representing ~0.19% of outstanding stock.

This Form 144/A shows a nominal insider sale relative to the issuer's outstanding shares: 3,836/2,046,854 equals approximately 0.187% of outstanding shares. The shares originate from a private placement dated 01/25/2022 and are being brokered through Merrill Lynch. The disclosed aggregate value is modest and unlikely to materially affect market capitalization or liquidity by itself. The filing helps maintain public transparency about proposed insider transactions but does not include trading execution results.

Compliance/Risk Analyst

TL;DR Disclosure appears procedurally complete but some filer identifiers are not present in the text provided.

The notice includes required elements: broker name and address, class, number of shares, acquisition date and nature (private placement), and the seller's declaration regarding material nonpublic information. However, the supplied content lacks explicit Filer CIK and filer identifiers in the provided text, which are typically required for full traceability. The filing states there were no sales in the past three months, reducing immediate compliance concern about undisclosed prior dispositions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144/A

144/A: Filer Information

Filer CIK
Filer CCC
Previous Accession Number Of The Filing
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144/A: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 824 A1A North Suite 200 Ponte Vedra Beach FL 32082	3836	53455.56	2046854	08/27/2025	NASQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/25/2022	Private Placement	Company			3836	01/25/2022	Private Placement

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Nothing to Report

144/A: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many shares is CVKD proposing to sell according to the Form 144/A?

The filing discloses a proposed sale of 3,836 common shares.

What is the aggregate market value of the proposed CVKD sale?

The aggregate market value is reported as $53,455.56.

When were the shares being sold originally acquired?

The shares were acquired on 01/25/2022 in a private placement from the company.

What percentage of CVKD's outstanding shares does this sale represent?

Based on the filing, 3,836 shares of 2,046,854 outstanding equals approximately 0.187% of shares outstanding.

Did the filer report any securities sold during the past three months?

The filing states Nothing to Report for securities sold in the past three months.

Does the filer assert there is no undisclosed material information?

Yes, the person for whose account the securities are to be sold represents they do not know any material adverse information not publicly disclosed.